On June 11, 2026, Apyx Medical Corporation appointed Stavros Vizirgianakis, the current Chairman of the Board, as Executive Chairman. In connection with this appointment, the Board granted Mr. Vizirgianakis 450,000 restricted stock units (RSUs). 150,000 RSUs vested immediately on June 11, 2026, while the remaining 300,000 RSUs will vest ratably over 12-month periods starting on the first and second anniversaries of the grant date, respectively. Mr. Vizirgianakis will provide strategic leadership and governance oversight but will not serve as an officer or employee. The company operates in the medical device industry, developing and commercializing medical technologies.